Women who have symptoms of breast cancer are sometimes referred to BreastScreen
Aotearoa (BSA) by their GP, or self refer to the programme. However, this has a
number of risks, including that the breast cancer may not be detected by a
mammogram and that there will be a delay in the diagnosis of breast cancer.
Dr Madeleine Wall, Clinical Leader, BreastScreen Aotearoa.
This overview of workforce development for BreastScreen Aotearoa (BSA) Medical Radiation Technologists (MRTs) and radiologists is part of the wider workforce initiatives for health professionals within the Ministry of Health.
This systematic review identified and appraised the international evidence for surveillance of women at high risk of breast cancer. The accuracy and health outcome of the following modalities of surveillance were assessed in comparison to normal care: mammography (XRM), ultrasound (US) and magnetic resonance imaging (MRI).
The purpose of this report is to present information on 2 year interval breast cancers from the BreastScreen Aotearoa (BSA) mammographic screening programme and to compare this with published results from other services.
Reviewing the evidence on the benefits, harms and costs of breast cancer screening for women aged 40 to 49 years in New Zealand. Simon Baker, Madeleine Wall, Ashley Bloomfield
The New Zealand Medical Journal. Vol 118 No1221 ISSN1175 8716
Reviewing the international evidence on the benefits and harms of different
screening intervals for women aged 45 to 49 years, and to inform the development of
a national policy.
Simon Baker, Madeleine Wall, Ashley Bloomfield. The New Zealand Medical Journal. Vol 118 No1221 ISSN1175 8716
Elana Curtis, Craig Wright, Madeleine Wall. The New Zealand Medical Journal Vol 118 No 1209 ISSN 1175 8716.
This article describes the methods used to estimate breast cancer incidence and mortality
in Maori and non-Maori women using multiple adjustors to assign ethnicity.